Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VIROPTIC | Monarch Pharmaceuticals | N-018299 RX | 1982-01-01 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LONSURF | Taiho Oncology | N-207981 RX | 2015-09-22 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
lonsurf | New Drug Application | 2024-12-10 |
trifluridine | ANDA | 2024-08-01 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
virus diseases | — | D014777 | B34 |
herpetic keratitis | EFO_0007308 | D016849 | — |
infectious keratoconjunctivitis | — | D007639 | — |
colorectal neoplasms | — | D015179 | — |
Expiration | Code | ||
---|---|---|---|
TIPIRACIL HYDROCHLORIDE / TRIFLURIDINE, LONSURF, TAIHO ONCOLOGY | |||
2026-02-22 | ODE-229 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colonic neoplasms | D003110 | — | C18 | 5 | 6 | — | — | — | 11 |
Rectal neoplasms | D012004 | — | — | 6 | 6 | — | — | — | 11 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 4 | — | — | — | 7 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 5 | — | — | — | 5 |
Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 5 | — | — | — | 5 |
Esophageal neoplasms | D004938 | — | C15 | 1 | 3 | — | — | — | 4 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | — | — | — | 4 |
Drug therapy | D004358 | — | — | 1 | 3 | — | — | — | 3 |
Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
Bile duct neoplasms | D001650 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 1 | 1 |
Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
Herpes simplex | D006561 | — | B00 | — | — | — | — | 1 | 1 |
Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | — | — | — | — | 1 | 1 |
Mycobacterium infections | D009164 | — | A31.9 | — | — | — | — | 1 | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 1 | 1 |
Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Trifluridine |
INN | trifluridine |
Description | Trifluridine is a pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis. It has a role as an antiviral drug, an antimetabolite, an EC 2.1.1.45 (thymidylate synthase) inhibitor and an antineoplastic agent. It is a nucleoside analogue, an organofluorine compound and a pyrimidine 2'-deoxyribonucleoside. |
Classification | Small molecule |
Drug class | antivirals; antineoplastics (uridine derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F |
PDB | — |
CAS-ID | 70-00-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1129 |
ChEBI ID | 75179 |
PubChem CID | 6256 |
DrugBank | DB00432 |
UNII ID | RMW9V5RW38 (ChemIDplus, GSRS) |